New Drug Shows Unprecedented Promise Against Deadly Pancreatic Cancer
Translated & summarized from Hamal by baba
A new drug, daraxonrasib, has shown unprecedented results in early trials for pancreatic cancer, with approximately 8.2% of patients experiencing complete tumor disappearance and 76.6% alive after one year. Presented by oncologists and hailed as a major breakthrough, the drug targets a common KRAS gene mutation. While already approved for some patient groups in the US and Europe, larger trials are ongoing, and the drug's high cost presents a barrier to access in Israel.
The story in 6 lines · by baba
- New drug daraxonrasib shows significant promise in early pancreatic cancer trials.
- Approximately 8.2% of patients in a trial saw tumors disappear completely.
- One-year survival rate in the trial reached 76.6%, far exceeding current standards.
- The drug targets the KRAS gene mutation common in over 90% of pancreatic tumors.
- US and European authorities have approved the drug for specific patient groups.
- Larger Phase 3 trials are underway to further evaluate the drug's efficacy.
A new drug, daraxonrasib, developed by American company Revolution Medicines, is showing remarkable results in early trials for pancreatic cancer, a disease notoriously difficult to treat. In a Phase 1/2 trial involving 61 newly diagnosed patients with metastatic pancreatic cancer, the drug, administered daily alongside standard chemotherapy, led to tumor shrinkage in 60.7% of patients, halted growth in 90.2%, and caused complete disappearance from scans in approximately 8.2%, or about one in 12 patients. Furthermore, 76.6% of patients were still alive one year after starting treatment, a significant improvement over the typical 40-45% survival rate for patients receiving only chemotherapy.
These groundbreaking findings were presented at a European Society for Medical Oncology conference in Barcelona by Dr. Woon-Kee Park, an oncologist at Memorial Sloan Kettering Cancer Center in New York, who called them a "huge, huge breakthrough." Michelle Mitchell, CEO of Cancer Research UK, described the results as "the biggest leap forward we have seen for decades." The drug targets a mutation in the KRAS gene, found in over 90% of pancreatic tumors, which constantly signals cancer cells to divide. Daraxonrasib locks onto the protein produced by this gene, silencing the signal.
This is not the first time daraxonrasib has made headlines. A previous Phase 3 trial of 500 patients who had already received prior treatment showed a median survival of 13.2 months with the drug, compared to 6.7 months with chemotherapy. This led to FDA approval in the U.S. on August 26 under the brand name Rasonque, followed by European Commission approval. However, these approvals are for patients who have already undergone prior treatment, not for newly diagnosed cases.
Despite the promising results, experts caution that the new trial had limitations, including the absence of a control group, a small sample size, and data originating from a company announcement rather than a peer-reviewed publication. The comparison to historical chemotherapy data, rather than concurrent controls, is also a point of note. Dr. Medina Kara of Pancreatic Cancer UK acknowledged it was a "small and early study."
A larger Phase 3 trial, RASolute 303, is currently evaluating daraxonrasib alone and in combination with chemotherapy against chemotherapy alone. In Israel, where about 1,000 people are diagnosed with pancreatic cancer annually, the drug is expected to be available via import, but at a high cost of approximately 90,000 shekels per month. While pancreatic cancer has not been conquered, the possibility of a one-in-12 complete remission offers significant hope, pending further results from Phase 3 trials and consideration by Israel's health basket committee.
Keep up with
Mentioned